

The SRT-100™ from SENSUS Healthcare Skin Cancer Treatment Simplified

The incidence of skin cancer has steadily increased over the past 75 years. During the 1930s, 1 in 1500 developed skin cancer. In 1960, the rate had risen to 1 in 600 and in 2000, the rate increased to 1 in 66. The National Cancer Institute estimates that 1 out of 5 is now at risk of developing some form of skin cancer during their lifetime. Increased exposure to the sun without skin protection and a decreasing natural ozone layer are cited as the chief causes of this increase. It is estimated that up to 1.3M new skin cancer cases are diagnosed annually in the United States and over 2.5M worldwide. This is projected to increase at a rate of 4% each year.

Over 50% of skin cancers occur in those over 60. This population also has a high incidence of risk for surgical procedures due to various disorders like diabetes and cardiac diseases that can slow the healing process. The traditional treatment path for non-melanoma skin cancer has been Mohs surgery. This surgery involves a series of excisions of cancerous tissue and surrounding healthy tissue until the cancer can no longer be detected. This procedure can lead to substantial cosmetic surgery requirements and a drawn-out healing process which can result in infection.

Sensus Healthcare recognised a need for a different solution for non-melanoma skin cancer treatment for those who have a high surgery risk. Because 80 percent of skin cancers occur in the head and neck regions, where surgery would require great tissue loss and significant cosmetic repair after surgery, Sensus looked to a 50-year proven technique, known as low energy radiotherapy which goes no deeper than the thickness of the skin to effectively treat non-melanoma skin cancer.

The SRT-100™ superficial radiotherapy system from Sensus Healthcare meets today's clinical and market needs by using state-of-the-art technology for efficient and effective treatment of non-melanoma skin cancer. Since the system received FDA approval during 2007, it's treated over 3,000 patients in the United States, Europe, South Africa and Australia and has already won a top award for its highly successful product innovation. The SRT 100™ is supplied and installed in the UK by Oncology Imaging Systems Ltd.

The system was developed by the same visionary who revolutionised dose-sensitive mammography technology in the 1980s. It provides patients with an alternative to surgery for treating basal cell and squamous cell skin cancers, especially primary lesions requiring difficult or extensive surgery with sensitive structures in the head and neck regions (the fold in the nose, eyelids, lips, corner of the mouth, and the lining of the ear) that would otherwise lead to a less than desirable cosmetic outcome.

The mobile and compact SRT-100™ helps bring safe, painless and effective non-melanoma skin cancer treatment to patients, right in the physician office. The low energy radiotherapy goes no deeper than the thickness of the skin. It is a proven non-invasive procedure that has been used to treat non-melanoma skin cancer for over 50 years and is highly recognised. Because the superficial x-rays concentrate radiation dose

on the skin surface, the treatment has several advantages over surgical procedures with considerably less chance of recurrence. The procedure is quick and virtually painless and doesn't require any anaesthetic. The healing process is faster with minimal to no scarring and virtually no risk of post-surgical infection or post procedure reconstruction.

The SRT 100™ is a compact, mobile, productive and cost effective solution for the non-surgical treatment of skin cancer. Created in consultation with the medical community, this system does not need a dedicated room and has a footprint of just 30" x 30"; it uses standard wall socket operation and offers automated set-up controls and modular component electrical assembly platforms. The unit produces filtered low-energy (70 and 100 kV) radiation from a conventional ceramic x-ray tube. There is a unique pre-treatment RAD check to verify dose delivery before the patient is treated, automatic X-ray tube warm-up and automatic Al filter change, precise dose delivery through a tube focal spot of 1mm x 1 mm and replaceable visual applicator safety contact shields.

The compact but flexible design has a broad range of motion (both horizontal and vertical) to allow the patient to be treated either sitting or lying down, especially comfortable for older people and those with restricted mobility. The reduction of set-up procedures, ease of use and reduced installation and operational costs, provides maximum system up-time and greatly improves a clinic's productivity and scheduling, whilst providing all patients with a considerably better, broader and more efficient treatment method.

The SRT 100™ was designed by TOPEX Inc. and acquired by SENSUS Healthcare to expand superficial radiotherapy clinical use and business development in the global marketplace. The first UK SRT 100™ was installed in Ipswich Hospital by Oncology Imaging Systems Ltd. In 2009.

For more information on the SRT 100™ and all our other patient positioning devices, please contact Oncology Imaging Systems Ltd., tel. 01825 840 633 fax. 01825 841 496 sales@oncologyimaging.com www.oncologyimaging.com